文献速递血液净化与透析肾血管病与高血压

腹膜透析患者高血压的评估与管理

Assessment and Management of Hypertension among Patients on Peritoneal Dialysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-10-19

本文综述腹膜透析(PD)患者高血压的流行病学、诊断与治疗证据。全球约7%-10%的ESKD患者接受PD治疗,PD与血液透析的高血压负担及血压与死亡率的预后关联模式相似,但容量控制策略需特别关注残余尿量和腹膜功能的长期保护。核心策略包括限钠、艾考糊精使用、腹膜保护及根据转运特性调整处方,降压药为二线治疗。

要点

  • PD患者高血压管理首选容量控制策略而非降压药物。
  • 限钠、艾考糊精、腹膜保护及个体化PD处方是核心措施。
  • 降压药用于容量管理后血压仍不达标者的二线治疗。

核心结论

  • PD与血液透析的高血压负担及血压与死亡率的预后关联模式相似,但PD容量控制需特别关注残余尿量和腹膜功能保护。

研究设计与样本

  • 本文为综述,回顾PD患者高血压流行病学、诊断和治疗的现有证据。

主要发现

  • 全球约7%-10%的ESKD患者接受PD作为肾脏替代治疗。
  • PD的持续性和无急性压力容量波动是与中心血液透析的重要区别。

关键数值与推荐

  • 限钠、适当使用艾考糊精、限制腹膜暴露于生物不相容溶液及根据腹膜转运特性调整PD处方为一线容量控制策略。
  • 降压药物为二线治疗,用于上述容量管理策略后血压仍无反应者。

临床怎么用

  • PD患者高血压管理应优先优化容量控制,包括限钠、艾考糊精和个体化PD处方。
  • 降压药物在容量管理优化后血压仍不达标时使用。

局限性

  • 本文呼吁开展随机试验以阐明PD人群高血压管理中的多个不确定领域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 7%-10% of patients with ESKD worldwide undergo peritoneal dialysis (PD) as kidney replacement therapy. The continuous nature of this dialytic modality and the absence of acute shifts in pressure and volume parameters is an important differentiation between PD and in-center hemodialysis. However, the burden of hypertension and prognostic association of BP with mortality follow comparable patterns in both modalities. Although management of hypertension uses similar therapeutic principles, long-term preservation of residual diuresis and longevity of peritoneal membrane function require particular attention in the prescription of the appropriate dialysis regimen among those on PD. Dietary sodium restriction, appropriate use of icodextrin, and limited exposure of peritoneal membrane to bioincompatible solutions, as well as adaptation of the PD regimen to the peritoneal transport characteristics, are first-line therapeutic strategies to achieve adequate volume control with a potential long-term benefit on technique survival. Antihypertensive drug therapy is a second-line therapeutic approach, used when BP remains unresponsive to the above volume management strategies. In this article, we review the available evidence on epidemiology, diagnosis, and treatment of hypertension among patients on PD and discuss similarities and differences between PD and in-center hemodialysis. We conclude with a call for randomized trials aiming to elucidate several areas of uncertainty in management of hypertension in the PD population.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Vaios V, Georgianos PI, Liakopoulos V, et al. Assessment and Management of Hypertension among Patients on Peritoneal Dialysis. Clin J Am Soc Nephrol. 2018. PMID: 30341090. doi:10.2215/CJN.07480618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。